Header Logo

Connection

MICHAEL ITTMANN to Gene Expression Regulation, Neoplastic

Back to Details
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Gene Expression Regulation, Neoplastic.
MICHAEL ITTMANN
Connection Strength
2.840
Gene Expression Regulation, Neoplastic
  1. MEX3D is an oncogenic driver in prostate cancer. Prostate. 2021 11; 81(15):1202-1213.
    View in: PubMed
    Score: 0.262
  2. RET Signaling in Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4885-4896.
    View in: PubMed
    Score: 0.195
  3. MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. Cancer Res. 2016 11 01; 76(21):6290-6298.
    View in: PubMed
    Score: 0.185
  4. FGF23 promotes prostate cancer progression. Oncotarget. 2015 Jul 10; 6(19):17291-301.
    View in: PubMed
    Score: 0.171
  5. Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest. 2015 Jul; 33(6):251-8.
    View in: PubMed
    Score: 0.169
  6. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 01; 73(9):2718-36.
    View in: PubMed
    Score: 0.147
  7. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009 Jun 15; 15(12):3979-89.
    View in: PubMed
    Score: 0.112
  8. DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. Epigenetics. 2009 Jan; 4(1):54-61.
    View in: PubMed
    Score: 0.109
  9. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia. 2008 Aug; 10(8):847-56.
    View in: PubMed
    Score: 0.106
  10. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008 Mar 13; 27(12):1788-93.
    View in: PubMed
    Score: 0.100
  11. Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate. 2006 Nov 01; 66(15):1641-52.
    View in: PubMed
    Score: 0.094
  12. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.066
  13. CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer Prostatic Dis. 2021 09; 24(3):891-902.
    View in: PubMed
    Score: 0.064
  14. Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity. Anticancer Res. 2019 Nov; 39(11):5861-5866.
    View in: PubMed
    Score: 0.058
  15. Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland. Cytokine. 2019 11; 123:154745.
    View in: PubMed
    Score: 0.056
  16. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999 May; 5(5):1063-71.
    View in: PubMed
    Score: 0.056
  17. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLoS One. 2014; 9(9):e106289.
    View in: PubMed
    Score: 0.040
  18. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 2014 Jan 01; 20(1):100-9.
    View in: PubMed
    Score: 0.038
  19. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):292-300.
    View in: PubMed
    Score: 0.037
  20. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013 Jun 15; 73(12):3716-24.
    View in: PubMed
    Score: 0.037
  21. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res. 2012 Jul 15; 18(14):3880-8.
    View in: PubMed
    Score: 0.034
  22. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011 Dec 15; 71(24):7694-704.
    View in: PubMed
    Score: 0.033
  23. Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. Prostate Cancer Prostatic Dis. 2011 Dec; 14(4):279-85.
    View in: PubMed
    Score: 0.033
  24. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One. 2011; 6(6):e21319.
    View in: PubMed
    Score: 0.032
  25. FGFR-4 Arg?88 enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res. 2011 Jul 01; 17(13):4355-66.
    View in: PubMed
    Score: 0.032
  26. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):9172-7.
    View in: PubMed
    Score: 0.032
  27. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate. 2006 Jun 01; 66(8):847-57.
    View in: PubMed
    Score: 0.023
  28. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate. 2006 May 01; 66(6):613-24.
    View in: PubMed
    Score: 0.023
  29. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer. 2006 Mar 15; 118(6):1471-80.
    View in: PubMed
    Score: 0.022
  30. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4701-6.
    View in: PubMed
    Score: 0.021
  31. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.021
  32. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004 Oct; 3(10):977-82.
    View in: PubMed
    Score: 0.020
  33. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004 Jul 15; 64(14):4728-35.
    View in: PubMed
    Score: 0.020
  34. Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer. Epigenetics. 2023 12; 18(1):2180585.
    View in: PubMed
    Score: 0.019
  35. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003 Sep 15; 63(18):5754-60.
    View in: PubMed
    Score: 0.019
  36. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021 11 01; 520:344-360.
    View in: PubMed
    Score: 0.016
  37. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene. 2021 03; 40(9):1690-1705.
    View in: PubMed
    Score: 0.016
  38. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 09; 10(9):1374-1387.
    View in: PubMed
    Score: 0.015
  39. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis. 2019 11 25; 40(11):1332-1340.
    View in: PubMed
    Score: 0.015
  40. JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. Nat Commun. 2019 05 14; 10(1):2148.
    View in: PubMed
    Score: 0.014
  41. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.
    View in: PubMed
    Score: 0.014
  42. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest. 2018 07 02; 128(7):3129-3143.
    View in: PubMed
    Score: 0.013
  43. Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. Clin Cancer Res. 2018 05 01; 24(9):2182-2193.
    View in: PubMed
    Score: 0.013
  44. A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis. Neoplasia. 2017 May; 19(5):421-428.
    View in: PubMed
    Score: 0.012
  45. Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. BMC Cancer. 2016 11 05; 16(1):853.
    View in: PubMed
    Score: 0.012
  46. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016 07 01; 126(7):2626-41.
    View in: PubMed
    Score: 0.011
  47. Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. Mol Cancer Res. 2016 Apr; 14(4):374-84.
    View in: PubMed
    Score: 0.011
  48. The role of ATP-binding cassette transporter genes in the progression of prostate cancer. Prostate. 2016 Apr; 76(5):434-44.
    View in: PubMed
    Score: 0.011
  49. Role of miR-145 in human laryngeal squamous cell carcinoma. Head Neck. 2016 Feb; 38(2):260-6.
    View in: PubMed
    Score: 0.011
  50. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics. 2015; 10(4):319-28.
    View in: PubMed
    Score: 0.011
  51. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest. 2015 Mar 02; 125(3):1174-88.
    View in: PubMed
    Score: 0.010
  52. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate. 2014 Nov; 74(15):1498-505.
    View in: PubMed
    Score: 0.010
  53. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.009
  54. ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC). PLoS One. 2013; 8(8):e72829.
    View in: PubMed
    Score: 0.009
  55. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol. 2013 Nov; 115(2):143-51.
    View in: PubMed
    Score: 0.009
  56. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res. 2013 Jul 01; 73(13):3997-4008.
    View in: PubMed
    Score: 0.009
  57. SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol. 2013 Jun; 27(6):925-39.
    View in: PubMed
    Score: 0.009
  58. ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res. 2013 Jul; 11(7):736-47.
    View in: PubMed
    Score: 0.009
  59. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol. 2013 Jun; 7(3):484-96.
    View in: PubMed
    Score: 0.009
  60. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012 Feb 01; 72(3):616-25.
    View in: PubMed
    Score: 0.008
  61. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.008
  62. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009 Feb 15; 8(4):580-8.
    View in: PubMed
    Score: 0.007
  63. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 2008 Aug 01; 123(3):543-51.
    View in: PubMed
    Score: 0.007
  64. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008 Jul 01; 68(13):5460-8.
    View in: PubMed
    Score: 0.007
  65. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008 Apr 30; 3(4):e2079.
    View in: PubMed
    Score: 0.007
  66. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007 Dec; 12(6):559-71.
    View in: PubMed
    Score: 0.006
  67. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.006
  68. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90.
    View in: PubMed
    Score: 0.005
  69. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004 Feb 01; 64(3):969-76.
    View in: PubMed
    Score: 0.005
  70. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003 Oct 01; 63(19):6237-43.
    View in: PubMed
    Score: 0.005
  71. A retrovirus carrying the K-fgf oncogene induces diffuse meningeal tumors and soft-tissue fibrosarcomas. Mol Cell Biol. 1993 Apr; 13(4):1998-2010.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.